An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers.
Akinyemi Oni-OrisanSony TutejaGlenda HoffeckerD Max SmithMatteo CastrichiniKristine R CrewsWilliam A MurphyNam H K NguyenYimei HuangChristelle LteifKevin A FriedeKelan TantisiraFolefac AminkengDeepak VooraLarisa H CavallariMichelle Whirl-CarrilloJulio D DuarteJasmine A Luzumnull nullPublished in: Clinical pharmacology and therapeutics (2023)
Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality.
Keyphrases
- healthcare
- clinical practice
- adverse drug
- cardiovascular disease
- primary care
- quality improvement
- systematic review
- metabolic syndrome
- type diabetes
- microbial community
- health information
- coronary artery disease
- chronic kidney disease
- insulin resistance
- end stage renal disease
- drug induced
- ejection fraction
- big data
- deep learning